KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Capital Expenditures: 2019-2024

Historic Capital Expenditures for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Dec 2024 value amounting to $13.7 million.

  • Recursion Pharmaceuticals' Capital Expenditures fell 94.67% to $243,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 million, marking a year-over-year decrease of 54.90%. This contributed to the annual value of $13.7 million for FY2024, which is 14.55% up from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported Capital Expenditures of $13.7 million as of FY2024, which was up 14.55% from $12.0 million recorded in FY2023.
  • In the past 5 years, Recursion Pharmaceuticals' Capital Expenditures ranged from a high of $39.8 million in FY2021 and a low of $5.8 million during FY2020.
  • For the 3-year period, Recursion Pharmaceuticals' Capital Expenditures averaged around $20.9 million, with its median value being $13.7 million (2024).
  • Per our database at Business Quant, Recursion Pharmaceuticals' Capital Expenditures skyrocketed by 582.52% in 2021 and then crashed by 67.74% in 2023.
  • Recursion Pharmaceuticals' Capital Expenditures (Yearly) stood at $5.8 million in 2020, then surged by 582.52% to $39.8 million in 2021, then dropped by 6.88% to $37.1 million in 2022, then slumped by 67.74% to $12.0 million in 2023, then increased by 14.55% to $13.7 million in 2024.